A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Aberrant extracellular matrix (ECM) deposition and stiffening is a physical hallmark of several solid cancers and is associated with therapy failure. BRAF-mutant melanomas treated with BRAF and MEK inhibitors almost invariably develop resistance that is frequently associated with transcriptional reprogramming and a de-differentiated cell state. Melanoma cells secrete their own ECM proteins, an event that is promoted by oncogenic BRAF inhibition. Yet, the contribution of cancer cell–derived ECM and tumor mechanics to drug adaptation and therapy resistance remains poorly understood. Here, we show that melanoma cells can adapt to targeted therapies through a mechanosignaling loop involving the autocrine remodeling of a drug-protective ECM. Analyses revealed that therapy-resistant cells associated with a mesenchymal dedifferentiated state displayed elevated responsiveness to collagen stiffening and force-mediated ECM remodeling through activation of actin-dependent mechanosensors Yes-associated protein (YAP) and myocardin-related transcription factor (MRTF). Short-term inhibition of MAPK pathway also induced mechanosignaling associated with deposition and remodeling of an aligned fibrillar matrix. This provided a favored ECM reorganization that promoted tolerance to BRAF inhibition in a YAP- and MRTF-dependent manner. Matrix remodeling and tumor stiffening were also observed in vivo upon exposure of BRAF-mutant melanoma cell lines or patient-derived xenograft models to MAPK pathway inhibition. Importantly, pharmacologic targeting of YAP reversed treatment-induced excessive collagen deposition, leading to enhancement of BRAF inhibitor efficacy. We conclude that MAPK pathway targeting therapies mechanically reprogram melanoma cells to confer a drug-protective matrix environment. Preventing melanoma cell mechanical reprogramming might be a promising therapeutic strategy for patients on targeted therapies. Significance: These findings reveal a biomechanical adaptation of melanoma cells to oncogenic BRAF pathway inhibition, which fuels a YAP/MRTF-dependent feed-forward loop associated with tumor stiffening, mechanosensing, and therapy resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398 · cited 1×
“Earlier studies have underscored the critical role of CAFs activated by BRAF inhibition for the development of resistant niches (27, 28, 31, 53).”
BackgroundRetractedThe extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“The ECM is a dynamic network of macromolecules with distinctive biochemical and mechanical properties that plays a major role in establishing tumor niches (1).”
BackgroundTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 1×
“Earlier studies have underscored the critical role of CAFs activated by BRAF inhibition for the development of resistant niches (27, 28, 31, 53).”
BackgroundCalvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381 · cited 1×
“YAP-TEAD and MRTF-SRF pathways functionally interact to coordinate mechanosignaling required for the maintenance of the CAF phenotype in solid tumors (7-9,50).”
BackgroundNaba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354 · cited 1×
“Interestingly, melanoma cells have the ability to secrete their own matrix, in particular upon cellular transition to a de-differentiated mesenchymal state occurring in response to BRAF inhibition (20, 32, 33).”
BackgroundPreparation of Hydrogel Substrates with Tunable Mechanical Properties
Tse, J. R., & Engler, A. J. (2010) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb1016s47 · Cited by 1,070 · cited 1×
“Immunofluorescence analysis Cells were grown on collagen-coated polyacrylamide/bisacrylamide synthetic hydrogels with defined stiffness as described (39), then rinsed, fixed in 4% formaldehyde, and incubated in PBS 0.”
MethodAcquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., Wong, D. J. L., Atefi, M., Shirazi, R., Wang, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.017 · Cited by 938 · cited 1×
“Melanoma comprises phenotypically heterogeneous subtypes of cancer cells that can switch between transcriptional programs and differentiation states (14-16).”
BackgroundReversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888 · cited 1×
“Differential gene expression was also examined in datasets derived from tumor biopsies from melanoma patients before and after development of drug resistance to BRAFi, MEKi, or BRAFi/MEKi combination [GSE50535 (25); Tirosh and colleagues (15)].”
Background
Cited by
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“Additionally, inhibition of oncogenic BRAF in melanoma cells induces autocrine, YAP1–MRTF-dependent remodelling of their secreted extracellular matrix, which is associated with tumour stiffening, mechanosensing and therapy resistance 265 .”
The RAC1 Target NCKAP1 Plays a Crucial Role in the Progression of Braf;Pten-Driven Melanoma in Mice
Swaminathan, K., Campbell, A., Papalazarou, V., Jaber-Hijazi, F., Nixon, C., McGhee, E., Strathdee, D., Sansom, O. J., & Machesky, L. M. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.029 · Cited by 18
Metadata
- Authors
- Girard, C. A., Lecacheur, M., Ben Jouira, R., Berestjuk, I., Diazzi, S., Prod'homme, V., Mallavialle, A., Larbret, F., Gesson, M., Schaub, S., Pisano, S., Audebert, S., Mari, B., Gaggioli, C., Leucci, E., Marine, J.-C., Deckert, M., & Tartare-Deckert, S.
- Venue
- Cancer Research
- Published
- 2020-05-15
- Volume
- 80
- Issue
- 10
- Pages
- 1927-1941
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W3010736313
- Cited by
- 70
- References
- 18
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-2914
- The paper
- Girard, C. A., Lecacheur, M., Ben Jouira, R., Berestjuk, I., Diazzi, S., Prod'homme, V., Mallavialle, A., Larbret, F., Gesson, M., Schaub, S., Pisano, S., Audebert, S., Mari, B., Gaggioli, C., Leucci, E., Marine, J.-C., Deckert, M., & Tartare-Deckert, S. (2020). A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-2914
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.